Drug Profile
Rabusertib
Alternative Names: IC-83; LY2603618Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma; ICOS Corporation
- Developer Eli Lilly and Company
- Class Antineoplastics; Morpholines; Pyrazines; Small molecules; Urea compounds
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 01 Jul 2016 Eli Lilly and Company completes its Phase-I trial for Solid tumours in Japan (NCT01341457)
- 26 Apr 2013 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, Late-stage disease) in Poland (IV)